Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Taysha Gene Therapies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TSHA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: TSHA's weekly volatility (10%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how TSHA performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how TSHA performed against the US Market.
Long-Term Price Volatility Vs. Market
How volatile is Taysha Gene Therapies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIndependent Director Paul Manning Just Bought A Handful Of Shares In Taysha Gene Therapies, Inc. (NASDAQ:TSHA)
3 months ago | Simply Wall StWe're Hopeful That Taysha Gene Therapies (NASDAQ:TSHA) Will Use Its Cash Wisely
5 months ago | Simply Wall StWhat Kind Of Shareholders Hold The Majority In Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares?
Is Taysha Gene Therapies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TSHA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TSHA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TSHA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: TSHA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TSHA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TSHA is overvalued based on its PB Ratio (4.4x) compared to the US Biotechs industry average (3.4x).
How is Taysha Gene Therapies forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TSHA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TSHA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TSHA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if TSHA's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if TSHA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TSHA is forecast to be unprofitable in 3 years.
How has Taysha Gene Therapies performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: TSHA is currently unprofitable.
Growing Profit Margin: TSHA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if TSHA's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare TSHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TSHA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: TSHA has a negative Return on Equity (-38.86%), as it is currently unprofitable.
How is Taysha Gene Therapies's financial position?
Financial Position Analysis
Short Term Liabilities: TSHA's short term assets ($239.6M) exceed its short term liabilities ($19.0M).
Long Term Liabilities: TSHA's short term assets ($239.6M) exceed its long term liabilities ($999.0K).
Debt to Equity History and Analysis
Debt Level: TSHA is debt free.
Reducing Debt: TSHA has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TSHA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: TSHA has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 137.5% each year.
What is Taysha Gene Therapies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TSHA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TSHA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TSHA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TSHA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TSHA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
R. Session (41 yo)
Mr. R. A. Session, II, is Founder, President, Chief Executive Officer and Director at Taysha Gene Therapies, Inc September 2019. Mr. Session serves as Entrepreneur-in-Residence of the University of Texas S...
CEO Compensation Analysis
Compensation vs Market: R.'s total compensation ($USD4.70M) is above average for companies of similar size in the US market ($USD2.38M).
Compensation vs Earnings: Insufficient data to compare R.'s compensation with company performance.
Experienced Management: TSHA's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Experienced Board: TSHA's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TSHA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: TSHA only recently listed within the past 12 months.
Taysha Gene Therapies, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Taysha Gene Therapies, Inc.
- Ticker: TSHA
- Exchange: NasdaqGS
- Founded: 2019
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$976.754m
- Shares outstanding: 37.92m
- Website: https://www.tayshagtx.com
Number of Employees
- Taysha Gene Therapies, Inc.
- 2280 Inwood Road
- United States
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous sys...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/19 23:23|
|End of Day Share Price||2021/06/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.